Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: A pilot study

ASAIO Journal

Volumn 52, Issue 4, 2006, Pages 398-403

  Hayakawa, Mineji ^a   Ito, Yasuko ^b   Fujita, Itaru ^b   Iseki, Ken ^b   Gando, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; DIALYSIS; MEDICAL APPLICATIONS; PATIENT TREATMENT; SURGERY; ULTRAFILTRATION;

DIALYSATE FLOWS (QD); PANIPENEM/BETA MIPRON; RENAL FAILURE; RENAL REPLACEMENT THERAPY (CRRT); ULTRAFILTRATE FLOWS (QF);

PHARMACOKINETICS;

CREATININE; PANIPENEM PLUS BETAMIPRON;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CALCULATION; CASE REPORT; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; FEMALE; HUMAN; MALE; PILOT STUDY; RENAL REPLACEMENT THERAPY;

ADOLESCENT; AGED; ANTI-BACTERIAL AGENTS; BODY HEIGHT; BODY WEIGHT; COMPUTER SIMULATION; CREATININE; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS; PILOT PROJECTS; RENAL REPLACEMENT THERAPY; THIENAMYCINS;

EID: 33746850581     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/0.1mat.0000225268.28044.ae     Document Type: Article

References (16)

1. Goa KL, Noble S: Panipenem/betamipron. Drugs 63: 913-925, 2003.
2. Shimada J, Kawahara Y: Overview of a new carbapenem, panipenem/ betamipron. Drugs Exp Clin Res 20: 241-245, 1994.
3. Yamaoka K, Tanigawara Y, Nakagawa T, et al : A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4: 879-885, 1981.
4. Clark WR, Ronco C: CRRT efficiency and efficacy in relation to solute size. Kidney Int Suppl 72: S3-S7, 1999.
5. NCCLS: Performance standard for microbial susceptibility testing. Wayne :M100-S12,2002.
6. Saito A, Inamatsu T, Okada J, et al: Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J Infect Chemother 5: 223-226, 1999.
7. Unal S, Masterton R, Goossens H: Bacteriemia in Europe: antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 23: 155-163, 2004.
8. Aoki N, Usuda Y, Koda Y, et al: Clinical pharmacology and efficacy of panipenem/betamipron [in Japanese]. Chemotherapy 39: 372-384, 1991.
9. Nakashima M, Uematsu T, Kanamaru M, et al: Phase I study of panipenem/betamipron I: single dose study [in Japanese]. Chemotherapy 39: 242-264, 1991.
10. Giles LJ, Jennings AC, Thomson AH, et al: Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 28: 632-637, 2000.
11. Krueger WA, Schroeder TH, Hutchison M, et al: Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 42: 2421-244, 1998.
12. Bohler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 72: S24-S28, 1999.
13. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356: 26-30, 2000.
14. Cole L, Bellomo R, Journois D, et al: High-volume haemofiltration in human septic shock. Intensive Care Med 27: 978-986, 2001.
15. Hyatt JM, McKinnon PS, Zimmer GS, et al: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 28: 143-160, 1995.
16. Naganuma H, Tokiwa H, Hirouchi Y, et al: Nephroprotective effect and its mechanism of betamipron (1): relationships of renal transport. Chemotherapy 39: 166-177, 1991.